Statements (43)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
recreational drug synthetic cathinone |
| gptkbp:actsOn |
serotonin-norepinephrine-dopamine reuptake inhibitor
releasing agent |
| gptkbp:appearance |
white to off-white crystalline powder
|
| gptkbp:CASNumber |
186028-79-5
|
| gptkbp:category |
recreational drug
phenethylamine derivative substituted cathinone |
| gptkbp:discoveredBy |
gptkb:Jacob_Peyton
|
| gptkbp:excretion |
gptkb:kidney
|
| gptkbp:firstSynthesized |
1996
|
| gptkbp:halfLife |
approximately 6 hours
|
| gptkbp:hasInChIKey |
InChI=1S/C11H13NO3/c1-7(12-2)6-8-3-4-9-10(5-8)15-7-11(13)14-9/h3-5,7,12H,6H2,1-2H3
|
| gptkbp:hasMolecularFormula |
C11H13NO3
|
| gptkbp:hasSMILES |
CC(CC1=CC2=C(C=C1)OCO2)NC
|
| https://www.w3.org/2000/01/rdf-schema#label |
Methylone
|
| gptkbp:IUPACName |
1-(1,3-benzodioxol-5-yl)-2-(methylamino)propan-1-one
|
| gptkbp:legal_status_(Canada) |
gptkb:Schedule_III
|
| gptkbp:legal_status_(UK) |
Class B drug
|
| gptkbp:legalStatus |
Schedule I controlled substance
|
| gptkbp:metabolism |
liver
|
| gptkbp:molecularWeight |
207.23 g/mol
|
| gptkbp:otherName |
gptkb:3,4-methylenedioxy-N-methylcathinone
gptkb:bk-MDMA |
| gptkbp:pharmacological_effect |
entactogen
stimulant empathogen |
| gptkbp:PubChem_CID |
2104677
21106398 45357845 |
| gptkbp:relatedTo |
gptkb:MDMA
gptkb:mephedrone |
| gptkbp:riskFactor |
potential for abuse
adverse effects include anxiety, agitation, tachycardia |
| gptkbp:routeOfAdministration |
injection
oral insufflation |
| gptkbp:UNII |
4U6Z3848E6
|
| gptkbp:usedFor |
recreational drug
|
| gptkbp:bfsParent |
gptkb:Too_High_to_Riot
|
| gptkbp:bfsLayer |
6
|